 Your new post is loading...
Your new post is loading...
|
Scooped by
Gilbert C FAURE
February 9, 2013 1:33 PM
|
Cuba Adds Two Vaccines against Advanced Lung Cancer Prensa Latina 09 de febrero de 2013, 10:36Havana, Feb 9(Prensa Latina) The registration of the Cuban vaccine RACOTUMOMAB, for the treatment of advanced lung cancer, was the most significant result...
|
|
Scooped by
Gilbert C FAURE
January 25, 2013 10:17 AM
|
RT @erikreinertsen: Nanogel vaccines targeting dendritic cells http://t.co/G2H24dRX via @JCRnEDITORS #biomaterials #immunology #bme
|
|
Scooped by
Gilbert C FAURE
January 24, 2013 2:17 PM
|
Vaccine News Daily (blog) Novel aptamer increases immune response to vaccines Vaccine News Daily (blog) “OX40-mediated signaling plays an important role in exacerbating the effects of certain inflammatory diseases such as experimental autoimmune...
|
|
Scooped by
Gilbert C FAURE
January 17, 2013 2:53 PM
|
The Engineer Prefab pharma The Engineer Jointly developed with German engineering and construction firm M&W Group, and launched late last year, Kubio is a modular biopharmaceutical plant chiefly aimed at the production of vaccines and monoclonal...
|
|
Scooped by
Gilbert C FAURE
December 7, 2012 1:26 PM
|
Lothar Stitz: A Vaccine for Every Strain of the FluBusinessweekLothar Stitz, a professor of veterinary medicine who researches virology and immunology at Germany's Friedrich Loeffler Institute, has come up with a method to produce flu vaccines in...
|
|
Scooped by
Gilbert C FAURE
November 27, 2012 9:46 AM
|
Proactive Investors AustraliaInovio Pharma's CMV synthetic vaccine constructs generate strong, broad T-cell ...pharmabiz.comInovio Pharmaceuticals, Inc., a company revolutionizing vaccines to prevent and treat today's cancers and challenging infectious...
|
|
Scooped by
Gilbert C FAURE
November 15, 2012 5:47 PM
|
Massively Expanding Stem Cell SuspensionsGenetic Engineering NewsIn conventional mammalian cell culture, the utilization of bioreactors is well established, e.g., for the production of recombinant therapeutic proteins, vaccines, and antibodies.
|
|
Scooped by
Gilbert C FAURE
November 14, 2012 3:10 PM
|
From BioPortfolio: The observational study would look at Dynavax�s Heplisav and GlaxoSmithKline�s Energerix-B, according to FDA briefing materials for the Vaccines...
|
|
Scooped by
Gilbert C FAURE
November 3, 2012 7:26 AM
|
Sun News NetworkMeth Vaccine Shows Promising Results in Early TestsSacramento BeeThese vaccines evoke antibody responses against drug molecules, just as traditional vaccines evoke antibody responses against viruses or bacteria.
|
|
Scooped by
Gilbert C FAURE
October 27, 2012 2:30 PM
|
Background: A 13-valent pneumococcal conjugate vaccine (PCV13) has been licensed in more than 100 countries to broaden coverage against pneumococcal disease.
|
|
Scooped by
Gilbert C FAURE
October 17, 2012 11:25 AM
|
DNA vaccination is a relatively recent development in vaccine methodology. It is now possible to undertake a rational step-by-step approach to DNA vaccine design.
|
|
Scooped by
Gilbert C FAURE
October 5, 2012 2:23 PM
|
AFP: Vaccines ready for 50 million in Africa's 'Meningitis Belt' http://t.co/iAdTN4Ha #health #medicine #immunology #infectdis...
|
|
Scooped by
Gilbert C FAURE
October 5, 2012 11:20 AM
|
Anti-cytokine vaccination: A new biotherapy of autoimmunity? Human vaccines: non-infectious diseases (Anti-cytokine vaccination: A new biotherapy of autoimmunity?
|
|
|
Scooped by
Gilbert C FAURE
January 27, 2013 11:30 AM
|
Translating breakthroughs in immunology into vaccines of global importance: vaccine event (RT @ImmunologyNews: RT @vaccineorb: Translating breakthroughs in immunology into vaccines of global importance (2013 meeting)
|
|
Scooped by
Gilbert C FAURE
January 24, 2013 2:53 PM
|
Novel aptamer boosts T cell-based immune response to therapeutic vaccines EurekAlert (press release) New Rochelle, NY, January 22, 2013—A small compound called an aptamer that specifically targets and stimulates a human immune cell can greatly...
|
|
Scooped by
Gilbert C FAURE
January 22, 2013 2:26 PM
|
Details of HER-2/neu Class I Antigen Licensed by TapImmune published in Journal of Immunology… http://t.co/n0wDpV9p
|
|
Scooped by
Gilbert C FAURE
December 19, 2012 1:39 PM
|
Free #BloodJournal: A case-control study to assess the risk of ITP associated with vaccines http://t.co/Bmu3W9r2 #thrombosis
|
|
Scooped by
Gilbert C FAURE
December 4, 2012 3:08 PM
|
HIV-AIDS Vaccines: Where Are We Now and Where Are We Heading?
|
|
Scooped by
Gilbert C FAURE
November 24, 2012 3:44 AM
|
MabVax Therapeutics Secures $5250000 New FinancingXconomy (blog)Concurrently, MabVax will create a pipeline of fully human monoclonal antibody products against each of the target antigens by using both the vaccines and the lymphocytes from successfully...
|
|
Scooped by
Gilbert C FAURE
November 15, 2012 5:45 PM
|
Allergy/Immunology Medical Article: Differential localization and function of antibody-forming cells responsive to inactivated or live-attenuated influenza virus vaccines (Differential localization and function of antibody-forming cells responsive...
|
|
Scooped by
Gilbert C FAURE
November 9, 2012 2:44 PM
|
Takeda, Japan's largest drugmaker, has started small in vaccines but is expanding with a recent acquisition and new recruits from rival companies, The Wall Street Journal reported.
|
|
Scooped by
Gilbert C FAURE
October 30, 2012 7:28 AM
|
WIPO patent: The disclosure relates to the development of improved methods for quantifying antigen in a vaccine composition in the absence of available antigen standards.
|
|
Scooped by
Gilbert C FAURE
October 18, 2012 11:48 AM
|
RT @VGXI: Targeted #DNAvaccines for enhanced induction of Idiotype (Id)-specific B and T cells | Frontiers in Tumor Immunity http://t.co/hwqMjSRY...
|
|
Scooped by
Gilbert C FAURE
October 16, 2012 11:39 AM
|
Novel-antigen influenza vaccines being investigated offer the potential of lasting, broad, and potent protection http://t.co/hb3sCXOp...
|
|
Scooped by
Gilbert C FAURE
October 5, 2012 2:23 PM
|
Present immunoprevention and immunotherapeutic approaches against cancer suffer from the limitation of being not (JTM article: Optimal MHC-II-restricted tumor antigen presentation to CD4+ T helper cells http://t.co/vuIfSHa2...)...
|
Scoop.it!
